Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypogonadotropic Hypogonadotropism Clear all
Completed Phase 2 Interventional Results available

A 6 Month Safety Extension Study of MBGS205

NCT02908074
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
BGS649
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
37
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neuropeptides in Human Reproduction

NCT01952782
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
Kisspeptin 112-121, Naloxone, GnRH
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism

NCT01739595
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
enclomiphene citrate, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Mobile, Alabama • Little Rock, Arkansas • Rancho Cucamonga, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Jul 23, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Hypogonadotropic Hypogonadism in Obese Young Males

NCT03245827
View directory record Official record
Conditions
Hypogonadism, Hypogonadotropic
Interventions
Clomiphene, Placebo
Drug
Lead sponsor
Sandeep Singh Dhindsa, M.D., F.A.C.E
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Regulation of Reproductive Hormones in Adult Men

NCT00392457
View directory record Official record
Conditions
Kallmann Syndrome, Hypogonadism, Gonadal Disorder
Interventions
ketoconazole, gonadotropin releasing hormone (GnRH)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Jul 23, 2026, 4:15 PM EDT
Terminated No phase listed Observational

Psychological Outcomes in Isolated GnRH Deficiency

NCT02356172
View directory record Official record
Conditions
Hypogonadism
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 200 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Jul 23, 2026, 4:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects on the Brain of Lupron Induced Hypogonadotropic Hypogonadism With and Without Testosterone Replacement

NCT00001412
View directory record Official record
Conditions
Hypogonadism
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 4:15 PM EDT
Completed No phase listed Observational

The Molecular Basis of Inherited Reproductive Disorders

NCT05971836
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Reproductive Disorder, Kallmann Syndrome, Delayed Puberty
Interventions
Not listed
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
1 Year and older
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Results available

Opioid Antagonism in Hypogonadotropic Hypogonadism

NCT04975334
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Low Testosterone
Interventions
Naloxone
Drug
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Low Energy Availability and Pituitary Function (LEAP Study)

NCT05808647
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
5-day controlled metabolic dietary intake
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Jul 23, 2026, 4:15 PM EDT
Recruiting Phase 2 Interventional

Kisspeptin Administration Subcutaneously to Patients With IHH

NCT05896293
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
kisspeptin 112-121, leuprolide acetate
Drug
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus

NCT01191320
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Secondary Hypogonadism
Interventions
Placebo, Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
20 Years to 80 Years · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Garden Grove, California • Sacramento, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)

NCT00392756
View directory record Official record
Conditions
Kallmann Syndrome, Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions
gonadotropin releasing hormone (GnRH)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2022 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism

NCT00493961
View directory record Official record
Conditions
Kallmann Syndrome, Idiopathic Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions
gonadotropin releasing hormone (GnRH)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Jul 23, 2026, 4:15 PM EDT
Recruiting No phase listed Observational

Inherited Reproductive Disorders

NCT01500447
View directory record Official record
Conditions
Genetic Disorder, Infertility, Hypogonadism, Amenorrhea
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
6 Weeks to 120 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
2
States / cities
Bethesda, Maryland • Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993225
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders

NCT05633966
View directory record Official record
Conditions
Hypothalamic Amenorrhea, Hypogonadotropic Hypogonadism
Interventions
Kisspeptin 112-121
Drug
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Jul 23, 2026, 4:15 PM EDT
Completed No phase listed Observational

Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders

NCT00494169
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Kallmann Syndrome, Puberty, Delayed, Puberty, Precocious, GnRH Deficiency
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
4,042 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

NCT01438073
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Healthy Postmenopausal Women, Agonadism
Interventions
kisspeptin 112-121, GnRH
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2022 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

NCT01532414
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Mobile, Alabama • Little Rock, Arkansas • Garden Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

NCT02730169
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
BGS649, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Jul 23, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men

NCT01200862
View directory record Official record
Conditions
Obese Hypogonadotropic Hypogonadism
Interventions
Investigational new drug company code: BGS649, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
30 Years to 65 Years · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Tucson, Arizona • San Diego, California • Miramar, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 4 Interventional

Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism

NCT03490513
View directory record Official record
Conditions
Hypogonadism, Hypogonadotropic, Obesity
Interventions
anastrozole (1 mg/day), Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
40 Years to 65 Years · Male only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Kisspeptin Administration in the Adult

NCT00914823
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Kallmann Syndrome, GnRH Deficiency, PCOS, Polycystic Ovarian Syndrome, Hyperprolactinemia
Interventions
kisspeptin 112-121, GnRH
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jul 23, 2026, 4:15 PM EDT